ALDEYRA THERAPEUTICS, INC. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ALDEYRA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-12-31 was $0.00.
- ALDEYRA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- ALDEYRA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $0.00.
- ALDEYRA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-03-31 was $19.62K, a 7.83% increase year-over-year.
- ALDEYRA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $19.62K, a 48.46% decline from fiscal 2024.
- ALDEYRA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $38.06K, a 65.74% decline from fiscal 2023.
- ALDEYRA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $111.10K, a 14.94% increase from fiscal 2022.
- ALDEYRA THERAPEUTICS, INC. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $96.67K, a 57.10% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $19.62K 10-K · filed 2026-02-27 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $19.62K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $39.48K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $19.62K 10-Q · filed 2026-05-07 | $39.48K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $38.06K 10-K · filed 2026-02-27 |
| 2024-09-30 | $19.87K 10-Q · filed 2025-11-05 | $38.06K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $76.73K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $18.19K 10-Q · filed 2025-05-14 | $76.73K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $111.10K 10-K · filed 2025-02-28 |
| 2023-09-30 | $58.54K 10-Q · filed 2024-11-07 | $111.10K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $125.90K derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $52.56K 10-Q · filed 2024-05-02 | $125.90K derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $96.67K 10-K · filed 2024-03-07 |
| 2022-09-30 | $73.34K 10-Q · filed 2023-11-03 | $96.67K derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $74.98K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $23.32K 10-Q · filed 2022-05-05 | $74.98K derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $61.53K 10-K · filed 2023-03-09 |
| 2021-09-30 | $51.65K 10-Q · filed 2021-10-28 | $61.53K derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $66.95K derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | $9.88K 10-Q · filed 2022-05-05 | $66.95K derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $126.97K 10-K · filed 2022-03-17 |
| 2020-09-30 | $57.08K 10-Q · filed 2020-11-05 | $126.97K derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $185.58K derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $69.89K 10-Q · filed 2021-05-06 | $264.74K derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $194.85K 10-K · filed 2021-03-11 |
| 2019-09-30 | $115.69K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $79.16K 10-Q · filed 2020-08-06 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $85.57K 10-K · filed 2020-03-12 |
| 2018-09-30 | $85.57K 10-Q · filed 2019-11-07 | |
| 2017-12-31 | $125.29K 10-K · filed 2019-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |